RET and lung cancer: Non–small cell lung cancer harboring a SMARCA4/SMARCA2 deficiency has no established treatment because it is mutually exclusive to genetic abnormalities such as EGFR mutations and anaplastic lymphoma kinase (ALK) and RET fusions, for which there are established treatments (53).